Pcn282 - Cancer Drugs Fund (Cdf) in the United Kingdom: A 2-Year Analysis

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.364
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcn299 - A Review of Appraisal Timelines in Oncology: Does Reimbursement Through the Cancer Drugs Fund (Cdf) Delay Patient Access?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn43 - A Targeted Review of Nice Single Technology Appraisals (Stas) in Urothelial Cancer Since the Introduction of the New Cancer Drugs Fund (Cdf)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comment on ‘Cancer Incidence in the United Kingdom: Projections to the Year 2030’

British Journal of Cancer
Cancer ResearchOncology
2013English

Increasing Use of Prescription Drugs in the United Kingdom

Pharmacoepidemiology and Drug Safety
EpidemiologyPharmacology
2015English

Pcn319 - RCT Not Rwe: Two Year Report Card for the Cancer Drugs Fund Reforms

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy182 - A Targeted Review of Haematology Single Technology Appraisals (Stas) by Nice Since the Introduction of the New Cancer Drugs Fund (Cdf)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cutbacks at England's Cancer Drugs Fund

Cancer Discovery
Oncology
2015English

Strengthening Clinical Cancer Research in the United Kingdom

British Journal of Cancer
Cancer ResearchOncology
2011English

UK Newspaper Reporting of the NHS Cancer Drugs Fund, 2010 to 2015: A Retrospective Media Analysis

Journal of the Royal Society of Medicine
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy